Lv0
0 积分 2022-11-11 加入
Potent Covalent Irreversible Inhibitor of KRAS G12C IBI351 in Patients with Advanced Solid Tumors: First-In-Human Phase I Study
12小时前
已完结
Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study
1个月前
已完结
Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study
1个月前
已关闭
Non–Small Cell Lung Cancer, Version 4.2024
3个月前
已完结
Non–Small Cell Lung Cancer, Version 4.2024
5个月前
已关闭
Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
7个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
7个月前
已完结
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
8个月前
已完结
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
8个月前
已完结
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
8个月前
已完结
皖公网安备34019202002308
